TickerLeague

EBITDA for IQVIA (IQV)

According to IQVIA's latest reported financial statements, the company's current EBITDA (TTM) is $3.46B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

TTM (last 4 quarters)

$3.46B

YoY change

+0.3%

5Y CAGR

+10.8%

Peak year (2025)

$3.46B

Cumulative EBITDA

$27.71B

EBITDA history chart for IQVIA (IQV) from 2010 to 2025

EBITDA history table for IQVIA (IQV) from 2010 to 2025

Fiscal yearPeriod endedReportedEBITDAYoY
2025$3.46B+0.3%
2024$3.45B+6.1%
2023$3.26B+11.9%
2022$2.91B+5.1%
2021$2.77B+33.3%
2020$2.08B+3.7%
2019$2.00B+6.3%
2018$1.88B+14.1%
2017$1.65B+94.5%
2016$849.00M+10.5%
2015$768.00M+6.2%
2014$723.00M+30.5%
2013$554.13M+10.8%
2012$500.09M+29.6%
2011$385.74M-17.5%
2010$467.37M

EBITDA values are taken from IQVIA's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

Analysis

2025's annual EBITDA for IQVIA (IQV) came in at $3.46B – edged up 0.3% year-over-year.

IQVIA EBITDA compound annual growth for the 2020–2025 (5 years) window is +10.8%, sustaining 14 straight years of year-over-year growth.

The dataset's maximum EBITDA sits at $3.46B (2025); the minimum reading of $385.74M dates to 2011.

IQVIA (IQV) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.

IQVIA EBITDA by Year

IQVIA EBITDA 2025: $3.46B

IQVIA EBITDA in 2025 was $3.46B, edged up 0.3% from 2024. This figure represents the highest annual value in the available history.

IQVIA EBITDA 2024: $3.45B

IQVIA EBITDA in 2024 was $3.45B, grew 6.1% from 2023.

IQVIA EBITDA 2023: $3.26B

IQVIA EBITDA in 2023 was $3.26B, grew 11.9% from 2022.

IQVIA EBITDA 2022: $2.91B

IQVIA EBITDA in 2022 was $2.91B, grew 5.1% from 2021.

IQVIA EBITDA 2021: $2.77B

IQVIA EBITDA in 2021 was $2.77B.

See more financial history for IQVIA (IQV).

Sector peers — EBITDA

Companies in the same sector as IQVIA, ranked by their latest EBITDA.

CompanyEBITDASector
Novo Nordisk A/S (NVO)$156.73BHealthcare
Johnson & Johnson (JNJ)$41.05BHealthcare
Eli Lilly and Company (LLY)$27.94BHealthcare
Merck & Co., Inc. (MRK)$25.36BHealthcare
UnitedHealth Group Incorporated (UNH)$23.06BHealthcare
AstraZeneca PLC (AZN)$19.83BHealthcare
AbbVie Inc. (ABBV)$17.63BHealthcare
Amgen Inc. (AMGN)$15.84BHealthcare

Frequently asked questions

What is IQVIA's EBITDA?

Latest reported EBITDA for IQVIA (IQV) is $3.46B (period ending December 31, 2025).

How has IQVIA EBITDA changed year-over-year?

IQVIA (IQV) EBITDA changed +0.3% year-over-year on the latest annual filing.

What is the long-term growth rate of IQVIA EBITDA?

IQVIA (IQV) EBITDA compound annual growth rate is +10.8% over the most recent 5 years available.

When did IQVIA EBITDA hit its highest annual value?

IQVIA EBITDA reached its highest annual value of $3.46B in 2025.

What was IQVIA EBITDA in 2024?

IQVIA (IQV) EBITDA in 2024 was $3.45B.

What was IQVIA EBITDA in 2025?

IQVIA (IQV) EBITDA in 2025 was $3.46B.

Metrics overview

Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.